Article info
PDFEconomic analysis
Cost-effectiveness
Current 10-year atherosclerotic cardiovascular disease risk threshold for statin eligibility is cost-effective for primary prevention
- Correspondence to : Dr Joseph Yeboah, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem NC 27157, USA; jyeboah{at}wakehealth.edu
Citation
Current 10-year atherosclerotic cardiovascular disease risk threshold for statin eligibility is cost-effective for primary prevention
Publication history
- First published September 2, 2015.
Online issue publication
December 09, 2020
Article Versions
- Previous version (9 December 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/